HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-07-17Clinical Trial Update: Pharmacokinetics of Low Dose Raltegravir [Phase 2]
Phase 2 trial update evaluating the pharmacokinetics of low-dose raltegravir in HIV infection.
-
CLINICAL_TRIALS trial_result · 2020-07-17Clinical Trial Update: Lopinavir (LPV) Dose Reduction [Phase 1, Phase 2]
Phase 1/2 trial update examining dose reduction of Lopinavir (LPV) in HIV-1 infections.
-
CLINICAL_TRIALS research · 2020-07-17Clinical Trial Update: Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection [Phase 1]
Phase 1 trial assessing safety and pharmacokinetics of raltegravir in HIV-1-exposed newborn infants at risk of acquiring HIV-1 infection; co…
-
CLINICAL_TRIALS trial_result · 2020-07-15Clinical Trial Update: Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV [Phase 2]
Phase 2 safety study evaluating a tenofovir-containing regimen for preventing mother-to-child transmission of HIV and hepatitis B has comple…
-
FDA approval · 2020-07-14FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-07-14FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ISENTRESS (raltegravir) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2020-07-14FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
FDA approves a supplemental application for JULUCA (dolutegravir sodium and rilpivirine hydrochloride) submitted by ViiV Healthcare Company.
-
FDA approval · 2020-07-14FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC. The action represents an updat…
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: Depression Therapy to Improve Cardiovascular Risk in HIV [NA]
Clinical trial on Depression Therapy aimed at improving cardiovascular risk in people with HIV has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2020-07-10Clinical Trial Update: Smartphone App and CO Self-monitoring for Smoking Cessation [Phase 4]
Phase 4 trial update on a smartphone app and carbon monoxide self-monitoring for smoking cessation; the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. [Phase 2]
Pilot Phase 2 trial exploring antiretroviral treatment guided by proviral genotype in HIV-1 infection.
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
A retrospective study assessing safety and efficacy of a nucleoside-sparing regimen (darunavir/ritonavir/dolutegravir) for HIV-1 infection.
-
FDA approval · 2020-07-02FDA Approved: RUKOBIA — Original Application (ViiV Healthcare Company)
FDA approved RUKOBIA (fostemsavir tromamine) via an original application to treat HIV-1 infection in adults with multidrug resistance, repre…
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: HIV Persistence and Viral Reservoirs [Phase 4]
Clinical trial update (Phase 4) on HIV persistence and viral reservoirs; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-30Clinical Trial Update: A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules [Phase 4]
A multicenter Phase 4 trial reports tolerability of once-daily lopinavir/ritonavir liquid compared with capsules in HIV infection.
-
CLINICAL_TRIALS research · 2020-06-30Clinical Trial Update: Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals [NA]
A completed clinical trial evaluating short-term disulfiram administration to accelerate decay of the HIV reservoir in antiretroviral-treate…
-
FDA approval · 2020-06-24FDA Approved: NEVIRAPINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for nevirapine from Camber Pharmaceuticals, approving changes to the generic product under an ab…
-
CLINICAL_TRIALS trial_result · 2020-06-24Clinical Trial Update: Buprenorphine to Improve HIV Care Engagement and Outcomes [Phase 4]
Phase 4 trial investigating buprenorphine to improve HIV care engagement and outcomes; study completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers [Phase 1]
Phase 1 pharmacokinetic study of long-acting cabotegravir in healthy adults completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen [Phase 4]
Phase 4 trial evaluating the effect of atorvastatin on aging-related complications in HIV-infected patients over 45 on protease inhibitor th…
-
FDA approval · 2020-06-18FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2020-06-18FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for RETROVIR (Zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2020-06-18FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Aptivus (tipranavir) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Life Plans Intervention Study [NA]
A completed clinical trial evaluating a Life Plans Intervention for people with HIV/AIDS and chronic HIV infection; results posted in 2020.
-
FDA approval · 2020-06-12FDA Approved: TIVICAY PD — Original Application (ViiV Healthcare Company)
FDA approved Tivicay PD (dolutegravir sodium) under an original application for HIV-1 infection, introducing a new product formulation of do…